Browse treatments

…t al. Immune resistance mechanisms and the road to personalized immunotherapy. Am Soc Clin Oncol Educ Book 2023;43:e390290.McCulloch JA, Dava…

…MMR defects in patients with solid tumours being considered for immunotherapy, use of a validated MSI NGS panel is another option.19 In the e…

…y to remodulate tumor stroma and restore or enhance response to immunotherapy in solid tumors.Methods In this work, we leverage ARTIDIS techn…

…e retrospectively analyzed 141 patients with NSCLC who received immunotherapy, including 9 monoimmunotherapy and 132 immunotherapy plus chemo…

…arges, and inpatient mortality in hospitalized adults receiving immunotherapy.Methods We analyzed the National Inpatient Sample (NIS) from 20…

…8Ga]Ga-PDL1p uptake, [18F]FDG uptake, and PD-L1 expression with immunotherapy response were analyzed, along with their predictive values for …

…nes how non-small cell lung cancer (NSCLC) survivors undergoing immunotherapy can experience reduced anxiety and psychological distress, impr…

…identify patients who are likely to have meaningful survival on immunotherapy.Ethics Approval The IRB protocol was approved by Einstein IRB.…

…, ‘non-small cell lung cancer’, ‘local consolidative therapy’, ‘local ablative therapy’, ‘stereotactic radiotherapy’, ‘SBRT’ and ‘SABR’. Searches were…

…rvival in patients with predominantly morning administration of immunotherapy. Whenever feasible, scheduling immunotherapy in the morning sho…

…In 2023 and 2024, 214 and 246 patients, respectively, initiated immunotherapy. Of these, 45 (21.03%) and 21 (8,5%) patients, respectively, di…

… was identified as a strong prognostic factor, showing enhanced immunotherapy responses. However, in cancer patients received ICIs, a thresho…